ArticlemAbs2026
HDX-MS-Guided computational modeling for rapid and accurate antibody-antigen interface mapping.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate mapping of paratopes and epitopes at antibody-antigen (Ab-Ag) interfaces is essential for the rational design of therapeutic antibodies in early drug development. Traditional methods for determining high-resolution Ab-Ag complex structures, such as X-ray crystallography and cryo-electron microscopy, are labor-intensive and require substantial time and resources. Although recent computational approaches have increased throughput, prediction accuracy and reliability remain limited, particularly without experimental structural constraints. Here, we present a hydrogen-deuterium exchange mass spectrometry (HDX-MS)-guided structural modeling workflow for efficient and accurate epitope and paratope mapping across three prospective case studies in therapeutic protein discovery and engineering. Across these systems, peptide-level HDX-MS data were sufficient to guide docking and structural modeling, whereas targeted electron transfer dissociation (ETD) HDX-MS was applied in one system as a higher-resolution, orthogonal approach to further localize critical binding residues. The workflow was applied to diverse Ab-Ag architectures spanning Fab and VHH binders and homodimeric and heterodimeric antigen ectodomains, and HDX-MS data were integrated with HADDOCK, AlphaFold2, and Protenix to generate Ab-Ag complex models. Comparison with subsequently obtained in-house X-ray crystal structures, used here as orthogonal high-resolution reference structures, showed strong agreement in overall binding orientation and interface placement. These results demonstrate the robustness and practical utility of this integrative approach for structure-informed antibody engineering in therapeutic protein discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.